ARS PHARMACEUTICALS I

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

20 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

05 Mar 2025 16:10:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

03 Mar 2025 16:35:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

20 Feb 2025 19:02:25 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

18 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference

05 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

21 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

13 Jan 2025 08:00:01 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

06 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

19 Dec 2024 17:25:09 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

18 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

12 Dec 2024 14:32:31 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

04 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

13 Nov 2024 06:30:01 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

11 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

24 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

23 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

10 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)

09 Sep 2024 16:47:16 By Nasdaq GlobeNewswire